CN115316341A - 一种雌激素温敏水凝胶混液及其制备方法和应用、子宫内膜异位症小鼠模型的构建方法 - Google Patents
一种雌激素温敏水凝胶混液及其制备方法和应用、子宫内膜异位症小鼠模型的构建方法 Download PDFInfo
- Publication number
- CN115316341A CN115316341A CN202210965589.3A CN202210965589A CN115316341A CN 115316341 A CN115316341 A CN 115316341A CN 202210965589 A CN202210965589 A CN 202210965589A CN 115316341 A CN115316341 A CN 115316341A
- Authority
- CN
- China
- Prior art keywords
- temperature
- estrogen
- sensitive hydrogel
- mixed solution
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940011871 estrogen Drugs 0.000 title claims abstract description 107
- 239000000262 estrogen Substances 0.000 title claims abstract description 107
- 239000000017 hydrogel Substances 0.000 title claims abstract description 94
- 239000011259 mixed solution Substances 0.000 title claims abstract description 38
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 31
- 238000010172 mouse model Methods 0.000 title claims abstract description 23
- 238000010276 construction Methods 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 13
- 239000004698 Polyethylene Substances 0.000 claims abstract description 4
- 229920000728 polyester Polymers 0.000 claims abstract description 4
- -1 polyethylene Polymers 0.000 claims abstract description 4
- 229920000573 polyethylene Polymers 0.000 claims abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 35
- 241000699670 Mus sp. Species 0.000 claims description 34
- 210000004291 uterus Anatomy 0.000 claims description 16
- 239000000499 gel Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- 238000002054 transplantation Methods 0.000 claims description 9
- 230000003187 abdominal effect Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 210000004696 endometrium Anatomy 0.000 claims description 5
- 210000000713 mesentery Anatomy 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 210000000683 abdominal cavity Anatomy 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 3
- 206010002091 Anaesthesia Diseases 0.000 claims description 3
- 101100018371 Arabidopsis thaliana ICR5 gene Proteins 0.000 claims description 3
- 230000037005 anaesthesia Effects 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- 210000004379 membrane Anatomy 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000003651 drinking water Substances 0.000 claims description 2
- 235000020188 drinking water Nutrition 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 230000009469 supplementation Effects 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 abstract description 14
- 238000010254 subcutaneous injection Methods 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 6
- 230000003442 weekly effect Effects 0.000 abstract description 5
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 208000031513 cyst Diseases 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010011732 Cyst Diseases 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000007939 sustained release tablet Substances 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920000382 poly(ethylene glycol) methyl ether-block-poly(L-lactide-co-glycolide) Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007281 self degradation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Animal Husbandry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210965589.3A CN115316341A (zh) | 2018-10-10 | 2018-10-10 | 一种雌激素温敏水凝胶混液及其制备方法和应用、子宫内膜异位症小鼠模型的构建方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210965589.3A CN115316341A (zh) | 2018-10-10 | 2018-10-10 | 一种雌激素温敏水凝胶混液及其制备方法和应用、子宫内膜异位症小鼠模型的构建方法 |
| CN201811176337.2A CN109481449A (zh) | 2018-10-10 | 2018-10-10 | 用于子宫内膜异位症小鼠模型建立的缓释混液及制备方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811176337.2A Division CN109481449A (zh) | 2018-10-10 | 2018-10-10 | 用于子宫内膜异位症小鼠模型建立的缓释混液及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115316341A true CN115316341A (zh) | 2022-11-11 |
Family
ID=65690242
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811176337.2A Pending CN109481449A (zh) | 2018-10-10 | 2018-10-10 | 用于子宫内膜异位症小鼠模型建立的缓释混液及制备方法 |
| CN202210965589.3A Pending CN115316341A (zh) | 2018-10-10 | 2018-10-10 | 一种雌激素温敏水凝胶混液及其制备方法和应用、子宫内膜异位症小鼠模型的构建方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811176337.2A Pending CN109481449A (zh) | 2018-10-10 | 2018-10-10 | 用于子宫内膜异位症小鼠模型建立的缓释混液及制备方法 |
Country Status (3)
| Country | Link |
|---|---|
| CN (2) | CN109481449A (de) |
| CH (1) | CH716073B1 (de) |
| WO (1) | WO2020073780A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481449A (zh) * | 2018-10-10 | 2019-03-19 | 浙江大学 | 用于子宫内膜异位症小鼠模型建立的缓释混液及制备方法 |
| CN115651119A (zh) * | 2022-09-28 | 2023-01-31 | 四川大学华西第二医院 | 一种雌激素缓释水凝胶及其制备方法和用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2377786A1 (en) * | 2002-03-20 | 2003-09-20 | Universite Laval | Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions |
| JP2004002321A (ja) * | 2002-03-11 | 2004-01-08 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患治療剤 |
| CN107106484A (zh) * | 2014-10-29 | 2017-08-29 | 雅戈泰克股份公司 | 胃滞留凝胶制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953774B (zh) * | 2010-09-17 | 2011-11-23 | 郑州大学 | 2-甲氧基雌二醇可注射水凝胶植入剂 |
| CN109481449A (zh) * | 2018-10-10 | 2019-03-19 | 浙江大学 | 用于子宫内膜异位症小鼠模型建立的缓释混液及制备方法 |
-
2018
- 2018-10-10 CN CN201811176337.2A patent/CN109481449A/zh active Pending
- 2018-10-10 CN CN202210965589.3A patent/CN115316341A/zh active Pending
-
2019
- 2019-09-19 WO PCT/CN2019/106729 patent/WO2020073780A1/zh active Application Filing
- 2019-09-19 CH CH01157/20A patent/CH716073B1/de not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004002321A (ja) * | 2002-03-11 | 2004-01-08 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患治療剤 |
| CA2377786A1 (en) * | 2002-03-20 | 2003-09-20 | Universite Laval | Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions |
| CN107106484A (zh) * | 2014-10-29 | 2017-08-29 | 雅戈泰克股份公司 | 胃滞留凝胶制剂 |
Non-Patent Citations (6)
| Title |
|---|
| 任婷婷等: "温度敏感型可注射水凝胶的性质及应用进展", 动物医学进展, pages 99 - 101 * |
| 周应芳: "小鼠皮下子宫内膜异位症模型的建立", 中国妇产科临床, pages 43 - 45 * |
| 宁维: "子宫内膜异位症动物模型发病极早期的VEGF 和MMP-2表达（一）", 临床与实验病理学杂志, pages 385 * |
| 易晓芳等: "子宫内膜异位症动物模型的研究进展", 现代妇产科进展, pages 291 - 293 * |
| 符旭东等: ""雌二醇阴道用温敏性凝胶的体外释药特性及局部滞留性评价", 中国药学杂志, pages 853 * |
| 马丽: "注射法小鼠皮下子宫内膜异位症模型及组织学观察", 中国实验动物学报, pages 192 - 195 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109481449A (zh) | 2019-03-19 |
| CH716073B1 (de) | 2023-02-28 |
| WO2020073780A1 (zh) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2668398T3 (es) | Composiciones y procedimientos para el relleno y la regeneración de tejidos | |
| McBride et al. | Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES | |
| CN109820816A (zh) | 温度敏感性生物凝胶制剂及其应用 | |
| MX2010008545A (es) | Anillos intravaginales monoliticos que comprenden progesterona y metodos de manufactura y uso de los mismos. | |
| CN115316341A (zh) | 一种雌激素温敏水凝胶混液及其制备方法和应用、子宫内膜异位症小鼠模型的构建方法 | |
| Kawakami et al. | Modified subcutaneous tissue with neovascularization is useful as the site for pancreatic islet transplantation | |
| CN110038163A (zh) | 一种用于修复腹壁缺损的水凝胶复合生物补片制备方法 | |
| CN108703942A (zh) | 载有纳米材料包裹保胎药物的微针给药系统及制备方法 | |
| Patel et al. | Off-Label use of Raloxifene hydrochloride in uterine fibroids: a novel insert-based formulation approach and IN-VIVO preclinical evaluation | |
| Wang et al. | Inflammation-induced subcutaneous neovascularization for the long-term survival of encapsulated islets without immunosuppression | |
| CN109381743A (zh) | 3d打印人造子宫内膜及其制备方法和应用 | |
| JP5911056B2 (ja) | ゼラチンビトリゲルとその製造方法、ゼラチンビトリゲルを利用した医療用素材、香粧品および食品素材と、ゼラチンゲル乾燥体、ゼラチンビトリゲル乾燥体とその製造方法 | |
| Chamorro et al. | Minced tissue in compressed collagen: a cell-containing biotransplant for single-staged reconstructive repair | |
| CN101336932B (zh) | 一种低传代猪毛乳头细胞培养上清液冻干粉 | |
| JP7454288B2 (ja) | 新規な獣用子宮注入剤の調製方法 | |
| CN113197842B (zh) | 一种大麻二酚可注射水凝胶、制备方法及其用途 | |
| CN109498557A (zh) | 一种氯前列醇钠注射液及其制备方法 | |
| RU2445074C1 (ru) | Лекарственная пленка пролонгированного действия, способ изготовления и способ ее применения | |
| CN105726464B (zh) | 一种麝香保心丸缓释凝胶剂用于药理研究的供试品制备方法 | |
| CN2362457Y (zh) | 人工睾丸 | |
| CN109568325A (zh) | 一种子宫内膜异位症纤维化动物模型构建方法及其应用 | |
| Schimidt et al. | The use of amniotic membrane in the repair of duodenal wounds in Wistar rats | |
| CN115837011B (zh) | 一种缓释乳糖酸的注射剂及乳糖酸微球在治疗薄型子宫内膜中的应用 | |
| US20240050625A1 (en) | Implant for ovarian decline and methods of manufacturing an implant for ovarian decline | |
| BR102020025563A2 (pt) | Método de obtenção de dispositivo vaginal de látex natural para liberação transmucosa sustentada de quimiocina e dispositivo vaginal obtido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |